133 related articles for article (PubMed ID: 3936564)
41. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
42. Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result.
Sekine H; Fukui I; Yamada T; Ohwada F; Yokokawa M; Ohshima H
J Urol; 1994 Jan; 151(1):27-30. PubMed ID: 8254827
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant intravesical chemotherapy of superficial bladder cancer with monthly doxorubicin or intensive mitomycin. A comparison of two consecutive series.
Ausfeld R; Beer M; Mühlethaler JP; Bartlome F; Widmer R; Tscholl R
Eur Urol; 1987; 13(1-2):10-4. PubMed ID: 3582437
[TBL] [Abstract][Full Text] [Related]
44. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial.
DeBruyne FM; van der Meijden AP; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg JJ
Urology; 1988 Mar; 31(3 Suppl):20-5. PubMed ID: 3279698
[TBL] [Abstract][Full Text] [Related]
45. Proteinuria after intravesical chemotherapy.
Cooper EH; Yu H; Glashan RW; Robinson MR; Newling DW
Prog Clin Biol Res; 1985; 185B():167-71. PubMed ID: 3929270
[No Abstract] [Full Text] [Related]
46. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
[No Abstract] [Full Text] [Related]
47. Evaluation of principles in intravesical chemo- and immunotherapy for superficial bladder cancer.
Jauhiainen K; Rintala E; Kaasinen E; Ruutu M; Alfthan O
Arch Esp Urol; 1990; 43 Suppl 2():159-64. PubMed ID: 2129004
[TBL] [Abstract][Full Text] [Related]
48. [Local mitomycin-C therapy of infiltrating bladder cancer].
Erdmann WD; Harzmann R; Flüchter SH; Bichler KH
Fortschr Med; 1984 Aug; 102(29-30):767-71. PubMed ID: 6437950
[TBL] [Abstract][Full Text] [Related]
49. [Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports].
Pouya M; Opsomer RJ; Wese FX; Saleh M; Donnay M; Van Cangh PJ
Acta Urol Belg; 1996 Mar; 64(1):47-53. PubMed ID: 8659335
[TBL] [Abstract][Full Text] [Related]
50. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor.
Kim HH; Lee C
J Urol; 1989 Jun; 141(6):1337-9; discussion 1339-40. PubMed ID: 2498532
[TBL] [Abstract][Full Text] [Related]
51. Bladder wall fibrosis following intravesical mitomycin treatment for superficial bladder cancer.
Katz G; Hackett RL; Wajsman Z
Urology; 1996 Jun; 47(6):928-9. PubMed ID: 8677595
[TBL] [Abstract][Full Text] [Related]
52. Follow up of patients receiving treatment for superficial bladder cancer with mitomycin C and BCG.
Soloway MS
Prog Clin Biol Res; 1990; 350():71-9. PubMed ID: 2117289
[TBL] [Abstract][Full Text] [Related]
53. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.
Malmström PU; Wijkström H; Lundholm C; Wester K; Busch C; Norlén BJ
J Urol; 1999 Apr; 161(4):1124-7. PubMed ID: 10081852
[TBL] [Abstract][Full Text] [Related]
54. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
55. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
[TBL] [Abstract][Full Text] [Related]
56. Intravesical mitomycin C for the treatment of carcinoma in situ of the bladder: 36 months follow-up.
Minervini R; Cecchi M; Felipetto R; Viganò L; Pagni G
Acta Urol Belg; 1994 Apr; 62(1):1-5. PubMed ID: 8197924
[TBL] [Abstract][Full Text] [Related]
57. Prostatic recurrences in the management of superficial bladder tumors.
Lockhart JL; Chaikin L; Bondhus MJ; Politano VA
J Urol; 1983 Aug; 130(2):256-7. PubMed ID: 6410083
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy.
Seo HK; Cho KS; Chung J; Joung JY; Park WS; Chung MK; Lee KH
Urology; 2010 Aug; 76(2):512.e1-7. PubMed ID: 20579709
[TBL] [Abstract][Full Text] [Related]
59. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
60. Renal failure after intravesical mitomycin C.
Farha AJ; Krauss DJ
Urology; 1989 Oct; 34(4):216-7. PubMed ID: 2508290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
